Shu Taishen (300204): BDB-001 quickly approved, COVID-19 clinical trials are expected to progress rapidly in the later stages
Shu Taishen (300204): Foreign Investment Rating Report (Overseas Institutional Investment Rating C)
Review of the semi-annual report of Shu Taishen (300204): The pressure on the transition period affected performance, Shu Taiqing's rapid growth and innovation continued
Shu Taishen (300204) Quarterly report comment: Shu Taiqing's growth rate is more than 50%. Su Pepsheng is under pressure and the transformation of innovation continues to advance.
Shu Taishen (300204) Annual report comments: Shu Taiqing's growth rate is close to 40%. The approved clinical extension of innovative monoclonal antibody is expected to continue to accelerate.
Shu Taishen (300204) three-quarter report comments: Shutai clear speed more than 30% of the overall performance in line with the expected innovation extension is expected to accelerate
Shu Taishen (300204) three-quarter report comments: smooth operation of the main business R & D mergers and acquisitions are worth looking forward to
Shu Taishen (300204) medium report comments: the performance is steady and meets the expectation. Shutai clear speed exceeds 30% innovation extension is expected to accelerate.
Shu Taishen (300204) Review: Su Pisheng's steady and sustained growth in R & D mergers and acquisitions is worth looking forward to.
Shu Taishen (300204) Quarterly report comments: Su Pisheng continues steady growth and pays attention to the progress of new products and extension
Review of the annual report of Shu Taishen (300204): Steady performance meets expectations, innovative research and development is progressing steadily
Review of the annual report of Shu Taishen (300204): Performance slightly exceeded expectations, focusing on the progress of R&D mergers and acquisitions
Shu Taishen (300204) 3rd Quarterly Report Review: Third Quarter Results Exceeded Market Expectations Future Core Focus on R&D
Shu Taishen (300204): The company plans to use over 100 million dollars to expand the peptide production workshop
Shu Taishen (300204): Cost control continues to expand to improve outreach and incentives advance smoothly
Shotaishen (300204) Quarterly Report Review: Steady Performance, New Varieties Worth Looking Forward to
Shu Taishen (300204) Quarterly Report Review: The main business is growing steadily and the products under development are rich
Shu Taishen (300204) comments: Release of draft equity incentives brings a secure boundary for performance
[Guangfa Securities] Shu Taishen: Draft Equity Incentives Released, Bringing Performance Security Boundaries
舒泰神(300204):业绩持续稳定增长 股权激励彰显信心
No Data